TRC is available to all existing Biomedtracker customers and is a core part of the BMT platform — not a separate add-on. It is also a key differentiating feature for prospects evaluating which tools best support competitive clinical analysis.
Primary Personas:
1. Competitive Intelligence (CI) Professionals
Core Use Case: Conducting head-to-head trial assessments to monitor competitor pipelines and understand how rival drugs are performing at key trial stages.
Key Value: Replaces fragmented, manual spreadsheet analysis with a single structured view; surfaces competitive threats and MOA performance by patient segment faster.
2. Portfolio Strategy Teams
Core Use Case: Evaluating which drugs are most likely to disrupt the standard of care (SoC) to shape investment decisions, positioning, and launch strategies.
Key Value: Determines which clinical profiles are strongest and how drugs stack up on key efficacy and safety metrics — directly informing go/no-go decisions.
3. BD&L Teams
Core Use Case: Assessing in-licensing deal candidates by comparing trial results across potential targets.
Key Value: Quickly evaluates the clinical profile strength of acquisition or licensing candidates without manual data aggregation.
4. Sell-Side Analysts
Core Use Case: Assessing pharma's late-stage pipeline for investment research and market commentary.
Key Value: Access AI-curated, side-by-side trial data supported by analyst commentary — reducing research time and increasing analytical depth.
Use Case Scenarios
Drug Profile Deep Dive: A CI professional navigates from a drug's product profile page and uses the "Compare Trial Results" link to instantly compare that drug's Phase 2/3 results against key competitors in the same indication — understanding efficacy differences and identifying which mechanism of action is performing best within a specific patient segment.
Disease-Level Competitive Scan: A portfolio strategist navigating an indication page — such as obesity or Alzheimer's — applies filters by phase, target, and MOA to create a curated comparison of the most relevant competing trials. This enables them to identify which drugs pose the greatest disruption risk to the standard of care.
BD&L Candidate Assessment: A BD&L team uses TRC to consolidate trial results for multiple in-licensing candidates across a shared indication, comparing safety signals and primary endpoint performance to inform and prioritize deal decisions.